Table 3 In vitro antifungal susceptibility of C. albicans between mono-CA-BSI and mixed-CA/B-BSIs
Candida species | Antifungalagent | mono-CA-BSI(n = 93) | mixed-CA/B-BSIs(n = 24) | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Number of strains | Drug sensitivity | Number of strains | Drug sensitivity | |||||||
S | I | R | S | I | R | |||||
C.albicans | Fluconazole(n = 104) a | 85(91.3%) | 81(95.3%) | 4(4.7%) | 0 | 19(79.1%) | 19(100.0%) | 0 | 0 | > 0.999 |
Clotrimazole(n = 69) a | 55(59.1%) | 54(98.2%) | 0 | 1(1.8%) | 15(62.5%) | 14(93.3%) | 0 | 0 | 0.901 | |
Ketoconazole(n = 60) a | 45(48.3%) | 19(42.2%) | 15(33.3%) | 11(24.4%) | 15(62.5%) | 7(46.7%) | 6(40.0%) | 2(13.3%) | 0.764 | |
Itraconazole(n = 111) a | 89(95.7%) | 86(96.6%) | 1(1.1%) | 2(2.2%) | 22(91.7%) | 21(95.5%) | 1(4.5%) | 0 | > 0.999 | |
Amphotericin B (n = 111) a | 90(96.8%) | 90(100.0%) | 0 | 0 | 21(87.5%) | 21(100.0%) | 0 | 0 | > 0.999 | |
Nystatin(n = 68) a | 56(60.2%) | 55(98.2%) | 1(1.8%) | 0 | 12(50.0%) | 12(100.0%) | 0 | 0 | > 0.999 | |
5-fluorocytosine(n = 38) a | 31(33.3%) | 30(96.8%) | 0 | 1(3.2%) | 7(29.1%) | 7(100.0%) | 0 | 0 | > 0.999 | |
Voriconazole(n = 103) a | 82(88.2%) | 82(100.0%) | 0 | 0 | 21(87.5%) | 21(100.0%) | 0 | 0 | > 0.999 | |